ClinicalTrials.gg
CompletedNCT06233786DysmenorrheaUpdated Sep 28, 2026

The Effectivenes of Non-invasive Neuromodulation in Adult Women With Primary Dysmenorrhea, Through the TENS Stimulation at Different Times of Menstrual Cycle in Each Group

An interventional study of Transcutaneous Electrical Nerve Stimulation (TENS) during bleeding phase and Transcutaneous Electrical Nerve Stimulation (TENS) during luteal phase in Primary Dysmenorrhea, sponsored by Naiara Benítez Aramburu. Completed at 1 site in Spain. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Naiara Benítez Aramburu · Not applicable, Interventional, and Treatment

How we know

Updated Sep 28, 2026Now CompletedPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Dysmenorrhea with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dysmenorrhea · Spain.

Enrollment
10th of 20
60 · median 60
Started
2024
with 4 others
No phase
16 of 23
1 open now
Registered
14th of 23
by date
Lead sponsor
1 of 23
Naiara Benítez Aramburu

Among the 23 studies in Dysmenorrhea with a site in Spain, this one is the 10th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2024, is one of 16 with no phase, and was the 14th registered.

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.

Browse Dysmenorrhea studies →

Open to participants now

3 of the 23 studies in Dysmenorrhea with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 12 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Dysmenorrhea with a site in Spain, or all of them as a file.
02

Study summary

The effectiveness of non-invasive neuromodulation in adult women with primary dysmenorrhea, through the TENS stimulation at different times in each group: during the bleeding phase (G1), between days 1 and 3 of menstrual cycle, and in the luteal phase (GI2), between days 17 to 24 of menstrual cycle.

The control group (CG) will be treated just like GI1, during the bleeding phase, but without the TENS transmitting the current. Participants will be evaluated by the NPRS, MPQ, SF12, CVM-22, HADS, PCS, PSQI and UDP in the first day of menstruation. Aditionally, GI1 and GC women, will be evaluated inmediatelly after the first sesion of treatment.

Read the detailed description

This RCT will evaluate women of legal age, with pain greater than 3 on the NPRS scale, and whose menstrual cycle is regular, considered regular between 25-30 days. The sample will be divided into a cases group, which in turn will be divided into 2 subgroups: stimulation intervention in women with dysmenorrhea during the bleeding phase (GI1), and in the luteal phase (GI2). On the other hand, the control group (CG) will be treated just like GI1, during the bleeding phase, but without the transcutaneous electrical nerve stimulation (TENS) transmitting the current.

Initially, a screening questionnaire will be completed. Subsequently, a first assessment will be done to all included participants, which will be conducted by completing the Numerical Pain Scale (NPRS) in relation to their pain for 7 days, McGill Pain Questionnaire (MPQ), SF12 Health Survey, Specific Quality of life Questionnaire Related to Menstruation (CVM-22), Hospital Anxiety and Depression Scale (HADS) and Pain Catastrophizing Scale (PCS) and Pittsburgh Sleep Quality Index (PSQI), as well as pressure pain threshold measure (PPT).

Participants of G1 and GC group, will contact the researcher again to comunicate again the first day of bleeding of this second cycle to being evaluated that same day (without 24 hours passing). In this case, the scales, questionnaires and PPT are done before the intervention in order to observe possible changes from one cycle to another, so that it can be seen if the improvement achieved after treatment has been due to the treatment or other factors. Once the intervention in the bleeding phase is completed, only pain and PTT will be assessed. A second session will be done after 48 hour, but without any data being collected this time, and repeating the assessment on the first day of bleeding of the third cycle.

Regarding GI2, the two interventions sessions will be executed in the middle of the luteal phase, considering 21 days after the cycle start. They will be evaluated again on the first day of the bleeding of the second cycle, within 24 hours, which is estimated to be 7 days after the intervention.

  • GI1: TENS stimulation in the bleeding phase (days 1 and 3)
  • GI2: TENS stimulation in the follicular phase (days between 17 and 24)
  • GC: Same procedure as GI1, but without TENS stimulation.

This intervention is performed using a TENS with an asymmetric biphasic wave of 200 µs width, frequency of 100Hz and maximum intensity tolerated by the participant, adapting to avoid accommodation. The intervention will be carried out for 30 minutes, once a day, and 2 days a week, with 48-72 hours between both interventions. Regarding the electrodes, 4 adhesive electrodes (5.0x5.0) will be placed, 2 in the lower lumbar region and two in the parasacral region (S2-S4).

03

Conditions studied

  • Primary Dysmenorrhea

Browse trials for

Keywords

  • Primary Dysmenorrhea
  • Transcutaneous Electrical Nerve Stimulation
  • Non-Invasive Neuromodulation
  • Sacral Surface Stimulation
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult women
  • Pain greater than 3 on the NPRS scale
  • Women with regular menstrual cycle, considered regular between 25-30 days

Exclusion criteria

Exclusion criteria:

  • Pregnancy or breastfeeding
  • Used of intrauterine device
  • Diagnosed gynaecological pathology: endometriosis, polycystic ovaries, uterine fibroid, adenomyosis, fibrosis, uterine malformation, pelvic inflammation, scars, SDT...
  • Skin lesions that prevent the placement of the electrodes
  • Other diagnosed pathologies that contraindicate the application of TENS, neurological pathologies, or cardiovascular diseases
  • Absence or doubling of bleeding in one month
  • Taking analgesic medications and/or NSAIDs
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    TENS in the bleeding phase

    Participants allocated to this arm will receive active TENS during the bleeding phase.

    Device: Transcutaneous Electrical Nerve Stimulation (TENS) during bleeding phase

  • Experimental
    TENS in the luteal phase

    Participants allocated to this arm will receive active TENS during the luteal phase.

    Device: Transcutaneous Electrical Nerve Stimulation (TENS) during luteal phase

  • Sham comparator
    Sham TENS in the bleeding phase

    Participants allocated to this arm will receive sham TENS during the bleeding phase.

    Device: Sham Transcutaneous Electrical Nerve Stimulation (TENS) during bleeding phase

Interventions

  • DeviceTranscutaneous Electrical Nerve Stimulation (TENS) during bleeding phase

    Transcutaneous electrical nerve stimulation will be applied for 30 minutes on the first and third days of menstrual bleeding using a TENS device with 4 electrodes placed bilaterally along the midline of the lumbosacral region.

  • DeviceTranscutaneous Electrical Nerve Stimulation (TENS) during luteal phase

    Transcutaneous electrical nerve stimulation will be applied for 30 minutes on cycle days 21 and 23, corresponding to the mid-luteal phase, using a TENS device with 4 electrodes placed bilaterally along the midline of the lumbosacral region.

  • DeviceSham Transcutaneous Electrical Nerve Stimulation (TENS) during bleeding phase

    The same procedure will be performed during the bleeding phase, but without delivering electrical current.

06

What researchers measure

Primary outcomes

  1. Pain: Numerical Pain Scale (NPRS)

    It evaluates the intensity of menstrual pain in this case. This scale is based on asking the patient about the intensity of their pain between a value of 0, which corresponds to the absence of pain, and a value of 10, which corresponds to the highest possible pain.

    Time frame: Pain intensity on the first day of menstrual bleeding will be assessed, in addition to the three days preceding and following it, across three consecutive cycles.

  2. Pressure pain threshold (PDU): Analog pressure algometer (Wagner FPX, United States)

    Pressure pain thresholds (PPTs) will be assessed in the abdominal and lumbar regions, corresponding to the usual areas of referred pain in women with dysmenorrhea. Five points will be evaluated in the lower abdominal region: two symmetrically located 4 cm from the umbilicus, two at the midpoint between the umbilicus and the anterior superior iliac spine, and one on the midline above the pubic symphysis (T10-T12). In the posterior region, the PPT will be measured at one point on the midline just below the last lumbar vertebra (L5), another at the central sacral level (S2-S4), and additionally at one point on the lateral wall of the right and left ischiorectal fossa. Bilateral assessments will also be conducted at control sites: the temporal region, the lateral aspect of the arm 10 cm below the lateral border of the acromion (C6-C7), and the anterior aspect of the thigh 15 cm above the superior edge of the patella (L2-L3).

    Time frame: Assessments will be conducted on the first day of menstrual bleeding (within 24h) across three consecutive cycles. In the second cycle, both groups will undergo two assessments instead of one, carried out before and after the first treatment session.

Secondary outcomes

  1. Anxiety and Depresion: Hospital Anxiety and Depression Scale (HADS)

    It is a 14-item self-administered questionnaire composed of two 7-item subscales: anxiety and depression. Each item is scored from 0 to 3, yielding subscale scores ranging from 0 to 21. Higher scores indicate greater symptom severity and a worse outcome of anxiety or depressive symptoms. The timeframe refers to the previous week.

    Time frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.

  2. Catastrophic thinking: Pain Catastrophizing Scale (PCS):

    It is a self-report inventory that assesses pain catastrophizing, composed of 13 items, which are grouped into 3 factors, which are cognitive rumination, magnification, and hopelessness. Using a five-point Likert scale (0, not at all; 1, a little; 2, moderately; 3, a lot; and 4, all the time), the informant rates the intensity with which she has experienced each thought while experiencing pain. The higher the score, the greater the pain catastrophizing, which could be a total of 52 points.

    Time frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.

  3. Sleep quality: Pittsburgh Sleep Quality Index (PSQI):

    It is a self-administered questionnaire that measures sleep quality, in addition to the subject's own perception of their sleep. It consists of 24 questions, of which 19 must be answered by the patient themselves (15 closed questions from 0 to 3, and 4 open), while 5 require feedback from the partner or roommate. The 19 self-assessed items are combined to form 7 scoring components (sleep quality, latency, duration, habitual efficiency, sleep disturbances, taking sleep medications, and daytime disturbances), each with a range of 0 to 3. A score of 0 points indicates that there is no difficulty, while a score of 3 corresponds to severe difficulty. The sum of the 7 components would give the global score, which has a range of 0 to 21 points, indicating severe difficulty in all the areas studied, as the score increase.

    Time frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.

  4. Quality of life: SF12 Health Questionnaire

    It evaluates multidimensional health and it consists of 12 items (physical function, social function, physical role, emotional role, mental health, vitality, body pain and general health). It is a self-administered questionnaire, where the number of response options ranges between 2 and 6, among which the patient can only choose one. This questionnaire allows to obtain two scores, which correspond to the physical summary and the mental summary. A higher score is related to better health status.

    Time frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.

  5. Pain: McGill Pain Index (MPQ)

    The McGill Pain Questionnaire (MPQ), developed by Melzack (1975), is a multidimensional tool with 78 descriptors across sensory, affective, evaluative, and miscellaneous dimensions. It characterizes pain quality and intensity through the Pain Rating Index (PRI) (0-78 total), Number of Words Chosen (NWC), and VAS (0-10). Higher PRI scores indicate greater pain severity.

    Time frame: Pain assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.

  6. Quality of life related to menstruation: Specific quality of life questionnaire related to menstruation (CVM-22)

    It assess the impact of menstruation on the woman's health status during bleeding days. The CVM-22 is a self-administered Likert-type questionnaire, made up of 22 items, where the questionnaire score ranges between 0 and 66, higher scores indicate worse quality of life.

    Time frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.

07

Study locations

1 site
  • Naiara Benítez Aramburu
    Torrelavega, Cantabria 39300, Spain
08

References and documents

Publications

  • Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update. 2015 Nov-Dec;21(6):762-78. doi: 10.1093/humupd/dmv039. Epub 2015 Sep 7. PubMed 26346058 ↗
  • Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl. 1986;3:S1-226. No abstract available. PubMed 3461421 ↗
  • ACOG Committee Opinion No. 760: Dysmenorrhea and Endometriosis in the Adolescent. Obstet Gynecol. 2018 Dec;132(6):e249-e258. doi: 10.1097/AOG.0000000000002978. PubMed 30461694 ↗
  • Coco AS. Primary dysmenorrhea. Am Fam Physician. 1999 Aug;60(2):489-96. PubMed 10465224 ↗
  • Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. BMJ. 2006 May 13;332(7550):1134-8. doi: 10.1136/bmj.332.7550.1134. No abstract available. PubMed 16690671 ↗
  • Osayande AS, Mehulic S. Diagnosis and initial management of dysmenorrhea. Am Fam Physician. 2014 Mar 1;89(5):341-6. PubMed 24695505 ↗
  • Chen CX, Shieh C, Draucker CB, Carpenter JS. Reasons women do not seek health care for dysmenorrhea. J Clin Nurs. 2018 Jan;27(1-2):e301-e308. doi: 10.1111/jocn.13946. Epub 2017 Sep 7. PubMed 28681499 ↗
  • Ramos-Pichardo JD, Ortega-Galan AM, Iglesias-Lopez MT, Abreu-Sanchez A, Fernandez-Martinez E. Why Do Some Spanish Nursing Students with Menstrual Pain Fail to Consult Healthcare Professionals? Int J Environ Res Public Health. 2020 Nov 5;17(21):8173. doi: 10.3390/ijerph17218173. PubMed 33167417 ↗
  • Weissman AM, Hartz AJ, Hansen MD, Johnson SR. The natural history of primary dysmenorrhoea: a longitudinal study. BJOG. 2004 Apr;111(4):345-52. doi: 10.1111/j.1471-0528.2004.00090.x. PubMed 15008771 ↗
  • Abreu-Sanchez A, Ruiz-Castillo J, Onieva-Zafra MD, Parra-Fernandez ML, Fernandez-Martinez E. Interference and Impact of Dysmenorrhea on the Life of Spanish Nursing Students. Int J Environ Res Public Health. 2020 Sep 5;17(18):6473. doi: 10.3390/ijerph17186473. PubMed 32899505 ↗
  • Karout S, Soubra L, Rahme D, Karout L, Khojah HMJ, Itani R. Prevalence, risk factors, and management practices of primary dysmenorrhea among young females. BMC Womens Health. 2021 Nov 8;21(1):392. doi: 10.1186/s12905-021-01532-w. PubMed 34749716 ↗
  • Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. 2006 Aug;108(2):428-41. doi: 10.1097/01.AOG.0000230214.26638.0c. PubMed 16880317 ↗
  • Dawood MY. Dysmenorrhoea and prostaglandins: pharmacological and therapeutic considerations. Drugs. 1981 Jul;22(1):42-56. doi: 10.2165/00003495-198122010-00003. PubMed 6790261 ↗
  • PICKLES VR. Myometrial responses to the menstrual plain muscle stimulant. J Endocrinol. 1959 Nov;19:150-7. doi: 10.1677/joe.0.0190150. No abstract available. PubMed 14432762 ↗
  • Maybin JA, Critchley HO. Menstrual physiology: implications for endometrial pathology and beyond. Hum Reprod Update. 2015 Nov-Dec;21(6):748-61. doi: 10.1093/humupd/dmv038. Epub 2015 Aug 7. PubMed 26253932 ↗
  • Messing K, Saurel-Cubizolles MJ, Bourgine M, Kaminski M. Factors associated with dysmenorrhea among workers in French poultry slaughterhouses and canneries. J Occup Med. 1993 May;35(5):493-500. PubMed 8515321 ↗
  • Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol. 1990 Jul;97(7):588-94. doi: 10.1111/j.1471-0528.1990.tb02545.x. PubMed 2390501 ↗
  • Harlow SD, Park M. A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women. Br J Obstet Gynaecol. 1996 Nov;103(11):1134-42. doi: 10.1111/j.1471-0528.1996.tb09597.x. PubMed 8917003 ↗
  • Hu Z, Tang L, Chen L, Kaminga AC, Xu H. Prevalence and Risk Factors Associated with Primary Dysmenorrhea among Chinese Female University Students: A Cross-sectional Study. J Pediatr Adolesc Gynecol. 2020 Feb;33(1):15-22. doi: 10.1016/j.jpag.2019.09.004. Epub 2019 Sep 17. PubMed 31539615 ↗
  • Thorbert G, Alm P, Owman C, Sjoberg NO, Sporrong B. Regional changes in structural and functional integrity of myometrial adrenergic nerves in pregnant guinea-pig, and their relationship to the localization of the conceptus. Acta Physiol Scand. 1978 Jun;103(2):120-31. doi: 10.1111/j.1748-1716.1978.tb06199.x. PubMed 676764 ↗
  • Montero P, Bernis C, Fernandez V, Castro S. Influence of body mass index and slimming habits on menstrual pain and cycle irregularity. J Biosoc Sci. 1996 Jul;28(3):315-23. doi: 10.1017/s0021932000022380. PubMed 8698711 ↗
  • Parazzini F, Tozzi L, Mezzopane R, Luchini L, Marchini M, Fedele L. Cigarette smoking, alcohol consumption, and risk of primary dysmenorrhea. Epidemiology. 1994 Jul;5(4):469-72. doi: 10.1097/00001648-199407000-00016. PubMed 7918820 ↗
  • Burnett M, Lemyre M. No. 345-Primary Dysmenorrhea Consensus Guideline. J Obstet Gynaecol Can. 2017 Jul;39(7):585-595. doi: 10.1016/j.jogc.2016.12.023. PubMed 28625286 ↗
  • Ferries-Rowe E, Corey E, Archer JS. Primary Dysmenorrhea: Diagnosis and Therapy. Obstet Gynecol. 2020 Nov;136(5):1047-1058. doi: 10.1097/AOG.0000000000004096. PubMed 33030880 ↗
  • Campbell MA, McGrath PJ. Use of medication by adolescents for the management of menstrual discomfort. Arch Pediatr Adolesc Med. 1997 Sep;151(9):905-13. doi: 10.1001/archpedi.1997.02170460043007. PubMed 9308868 ↗
  • Dawood MY. Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med. 1988 May 20;84(5A):23-9. doi: 10.1016/0002-9343(88)90473-1. PubMed 3287908 ↗
  • Parra-Fernandez ML, Onieva-Zafra MD, Abreu-Sanchez A, Ramos-Pichardo JD, Iglesias-Lopez MT, Fernandez-Martinez E. Management of Primary Dysmenorrhea among University Students in the South of Spain and Family Influence. Int J Environ Res Public Health. 2020 Aug 1;17(15):5570. doi: 10.3390/ijerph17155570. PubMed 32752254 ↗
  • Dmitrovic R, Kunselman AR, Legro RS. Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol. 2012 Jun;119(6):1143-50. doi: 10.1097/AOG.0b013e318257217a. PubMed 22617578 ↗
  • Edelman A, Micks E, Gallo MF, Jensen JT, Grimes DA. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2014 Jul 29;2014(7):CD004695. doi: 10.1002/14651858.CD004695.pub3. PubMed 25072731 ↗
  • Milsom I, Hedner N, Mannheimer C. A comparative study of the effect of high-intensity transcutaneous nerve stimulation and oral naproxen on intrauterine pressure and menstrual pain in patients with primary dysmenorrhea. Am J Obstet Gynecol. 1994 Jan;170(1 Pt 1):123-9. doi: 10.1016/s0002-9378(94)70396-5. PubMed 8296814 ↗
  • Ruoff G, Lema M. Strategies in pain management: new and potential indications for COX-2 specific inhibitors. J Pain Symptom Manage. 2003 Feb;25(2 Suppl):S21-31. doi: 10.1016/s0885-3924(02)00628-0. PubMed 12604154 ↗
  • Di Girolamo G, Sanchez AJ, De Los Santos AR, Gonzalez CD. Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea? Expert Opin Pharmacother. 2004 Mar;5(3):561-70. doi: 10.1517/14656566.5.3.561. PubMed 15013925 ↗
  • Abubakar U, Zulkarnain AI, Samri F, Hisham SR, Alias A, Ishak M, Sugiman H, Ghozali T. Use of complementary and alternative therapies for the treatment of dysmenorrhea among undergraduate pharmacy students in Malaysia: a cross sectional study. BMC Complement Med Ther. 2020 Sep 18;20(1):285. doi: 10.1186/s12906-020-03082-4. PubMed 32948163 ↗
  • Akin MD, Weingand KW, Hengehold DA, Goodale MB, Hinkle RT, Smith RP. Continuous low-level topical heat in the treatment of dysmenorrhea. Obstet Gynecol. 2001 Mar;97(3):343-9. doi: 10.1016/s0029-7844(00)01163-7. PubMed 11239634 ↗
  • Armour M, Smith CA, Steel KA, Macmillan F. The effectiveness of self-care and lifestyle interventions in primary dysmenorrhea: a systematic review and meta-analysis. BMC Complement Altern Med. 2019 Jan 17;19(1):22. doi: 10.1186/s12906-019-2433-8. PubMed 30654775 ↗
  • Armour M, Ee CC, Naidoo D, Ayati Z, Chalmers KJ, Steel KA, de Manincor MJ, Delshad E. Exercise for dysmenorrhoea. Cochrane Database Syst Rev. 2019 Sep 20;9(9):CD004142. doi: 10.1002/14651858.CD004142.pub4. PubMed 31538328 ↗
  • Tsonis O, Gkrozou F, Barmpalia Z, Makopoulou A, Siafaka V. Integrating Lifestyle Focused Approaches into the Management of Primary Dysmenorrhea: Impact on Quality of Life. Int J Womens Health. 2021 Mar 17;13:327-336. doi: 10.2147/IJWH.S264023. eCollection 2021. PubMed 33762855 ↗
  • Jaleel G, Shaphe MA, Khan AR, Malhotra D, Khan H, Parveen S, Qasheesh M, Beg RA, Chahal A, Ahmad F, Ahmad MF. Effect of Exercises on Central and Endocrine System for Pain Modulation in Primary Dysmenorrhea. J Lifestyle Med. 2022 Jan 31;12(1):15-25. doi: 10.15280/jlm.2022.12.1.15. PubMed 35300040 ↗
  • Lopez-Liria R, Torres-Alamo L, Vega-Ramirez FA, Garcia-Luengo AV, Aguilar-Parra JM, Trigueros-Ramos R, Rocamora-Perez P. Efficacy of Physiotherapy Treatment in Primary Dysmenorrhea: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2021 Jul 23;18(15):7832. doi: 10.3390/ijerph18157832. PubMed 34360122 ↗
  • Ortiz MI, Cortes-Marquez SK, Romero-Quezada LC, Murguia-Canovas G, Jaramillo-Diaz AP. Effect of a physiotherapy program in women with primary dysmenorrhea. Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:24-9. doi: 10.1016/j.ejogrb.2015.08.008. Epub 2015 Aug 17. PubMed 26319652 ↗
  • Azima S, Bakhshayesh HR, Kaviani M, Abbasnia K, Sayadi M. Comparison of the Effect of Massage Therapy and Isometric Exercises on Primary Dysmenorrhea: A Randomized Controlled Clinical Trial. J Pediatr Adolesc Gynecol. 2015 Dec;28(6):486-91. doi: 10.1016/j.jpag.2015.02.003. Epub 2015 Mar 5. PubMed 26272447 ↗
  • Gaubeca-Gilarranz A, Fernandez-de-Las-Penas C, Medina-Torres JR, Seoane-Ruiz JM, Company-Palones A, Cleland JA, Arias-Buria JL. Effectiveness of dry needling of rectus abdominis trigger points for the treatment of primary dysmenorrhoea: a randomised parallel-group trial. Acupunct Med. 2018 Oct;36(5):302-310. doi: 10.1136/acupmed-2017-011566. Epub 2018 May 2. PubMed 29720379 ↗
  • Smith CA, Armour M, Zhu X, Li X, Lu ZY, Song J. Acupuncture for dysmenorrhoea. Cochrane Database Syst Rev. 2016 Apr 18;4(4):CD007854. doi: 10.1002/14651858.CD007854.pub3. PubMed 27087494 ↗
  • Sharghi M, Mansurkhani SM, Larky DA, Kooti W, Niksefat M, Firoozbakht M, Behzadifar M, Azami M, Servatyari K, Jouybari L. An update and systematic review on the treatment of primary dysmenorrhea. JBRA Assist Reprod. 2019 Jan 31;23(1):51-57. doi: 10.5935/1518-0557.20180083. PubMed 30521155 ↗
  • Abaraogu UO, Igwe SE, Tabansi-Ochiogu CS, Duru DO. A Systematic Review and Meta-Analysis of the Efficacy of Manipulative Therapy in Women with Primary Dysmenorrhea. Explore (NY). 2017 Nov-Dec;13(6):386-392. doi: 10.1016/j.explore.2017.08.001. Epub 2017 Aug 30. PubMed 28988817 ↗
  • Dogan H, Eroglu S, Akbayrak T. The effect of kinesio taping and lifestyle changes on pain, body awareness and quality of life in primary dysmenorrhea. Complement Ther Clin Pract. 2020 May;39:101120. doi: 10.1016/j.ctcp.2020.101120. Epub 2020 Feb 22. PubMed 32379659 ↗
  • Apay SE, Arslan S, Akpinar RB, Celebioglu A. Effect of aromatherapy massage on dysmenorrhea in Turkish students. Pain Manag Nurs. 2012 Dec;13(4):236-40. doi: 10.1016/j.pmn.2010.04.002. Epub 2010 Sep 15. PubMed 23158705 ↗
  • Lee MS, Lee HW, Khalil M, Lim HS, Lim HJ. Aromatherapy for Managing Pain in Primary Dysmenorrhea: A Systematic Review of Randomized Placebo-Controlled Trials. J Clin Med. 2018 Nov 10;7(11):434. doi: 10.3390/jcm7110434. PubMed 30423839 ↗
  • Lauretti GR, Oliveira R, Parada F, Mattos AL. The New Portable Transcutaneous Electrical Nerve Stimulation Device Was Efficacious in the Control of Primary Dysmenorrhea Cramp Pain. Neuromodulation. 2015 Aug;18(6):522-6; discussion 522-7. doi: 10.1111/ner.12269. Epub 2015 Feb 5. PubMed 25655828 ↗
  • Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965 Nov 19;150(3699):971-9. doi: 10.1126/science.150.3699.971. No abstract available. PubMed 5320816 ↗
  • Treede RD. Gain control mechanisms in the nociceptive system. Pain. 2016 Jun;157(6):1199-1204. doi: 10.1097/j.pain.0000000000000499. PubMed 26817644 ↗
  • Mayer DJ, Hayes RL. Stimulation-produced analgesia: development of tolerance and cross-tolerance to morphine. Science. 1975 May 30;188(4191):941-3. doi: 10.1126/science.1094537. PubMed 1094537 ↗
  • Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia-- imaging a shared neuronal network. Science. 2002 Mar 1;295(5560):1737-40. doi: 10.1126/science.1067176. Epub 2002 Feb 7. PubMed 11834781 ↗
  • Wang SF, Lee JP, Hwa HL. Effect of transcutaneous electrical nerve stimulation on primary dysmenorrhea. Neuromodulation. 2009 Oct;12(4):302-9. doi: 10.1111/j.1525-1403.2009.00226.x. Epub 2009 Aug 20. PubMed 22151421 ↗
  • Vance CG, Dailey DL, Rakel BA, Sluka KA. Using TENS for pain control: the state of the evidence. Pain Manag. 2014 May;4(3):197-209. doi: 10.2217/pmt.14.13. PubMed 24953072 ↗
  • Budgell BS, Sovak G, Soave D. TENS augments blood flow in somatotopically linked spinal cord segments and mitigates compressive ischemia. Spinal Cord. 2014 Oct;52(10):744-8. doi: 10.1038/sc.2014.120. Epub 2014 Jul 22. PubMed 25047054 ↗
  • Dawood MY, Ramos J. Transcutaneous electrical nerve stimulation (TENS) for the treatment of primary dysmenorrhea: a randomized crossover comparison with placebo TENS and ibuprofen. Obstet Gynecol. 1990 Apr;75(4):656-60. PubMed 2179780 ↗
  • Lewers D, Clelland JA, Jackson JR, Varner RE, Bergman J. Transcutaneous electrical nerve stimulation in the relief of primary dysmenorrhea. Phys Ther. 1989 Jan;69(1):3-9. doi: 10.1093/ptj/69.1.3. PubMed 2783493 ↗
  • Elboim-Gabyzon M, Kalichman L. Transcutaneous Electrical Nerve Stimulation (TENS) for Primary Dysmenorrhea: An Overview. Int J Womens Health. 2020 Jan 8;12:1-10. doi: 10.2147/IJWH.S220523. eCollection 2020. PubMed 32021488 ↗
  • Proctor ML, Smith CA, Farquhar CM, Stones RW. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea. Cochrane Database Syst Rev. 2002;2002(1):CD002123. doi: 10.1002/14651858.CD002123. PubMed 11869624 ↗
  • Bai HY, Bai HY, Yang ZQ. Effect of transcutaneous electrical nerve stimulation therapy for the treatment of primary dysmenorrheal. Medicine (Baltimore). 2017 Sep;96(36):e7959. doi: 10.1097/MD.0000000000007959. PubMed 28885348 ↗
  • Bergeron-Vezina K, Leonard G. On "what makes transcutaneous electrical nerve stimulation work?..." Sluka KA, Bjordal JM, Marchand S, Rakel BA. Phys Ther. 2013;93:1397-1402. Phys Ther. 2013 Oct;93(10):1426-7. doi: 10.2522/ptj.2013.93.10.1426. No abstract available. PubMed 24086069 ↗
  • Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975 Sep;1(3):277-299. doi: 10.1016/0304-3959(75)90044-5. PubMed 1235985 ↗
  • Reading AE. The internal structure of the McGill pain questionnaire in dysmenorrhoea patients. Pain. 1979 Dec;7(3):353-358. doi: 10.1016/0304-3959(79)90091-5. PubMed 530741 ↗
  • Lazaro C, Caseras X, Whizar-Lugo VM, Wenk R, Baldioceda F, Bernal R, Ovalle A, Torrubia R, Banos JE. Psychometric properties of a Spanish version of the McGill Pain Questionnaire in several Spanish-speaking countries. Clin J Pain. 2001 Dec;17(4):365-74. doi: 10.1097/00002508-200112000-00012. PubMed 11783818 ↗
  • Masedo AI, Esteve R. Some empirical evidence regarding the validity of the Spanish version of the McGill Pain Questionnaire (MPQ-SV). Pain. 2000 Apr;85(3):451-456. doi: 10.1016/S0304-3959(99)00300-0. PubMed 10781918 ↗
  • Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52. doi: 10.1002/acr.20543. No abstract available. PubMed 22588748 ↗
  • Vilagut G, Valderas JM, Ferrer M, Garin O, Lopez-Garcia E, Alonso J. [Interpretation of SF-36 and SF-12 questionnaires in Spain: physical and mental components]. Med Clin (Barc). 2008 May 24;130(19):726-35. doi: 10.1157/13121076. Spanish. PubMed 18570798 ↗
  • Monteagudo Piqueras O, Hernando Arizaleta L, Palomar Rodriguez JA. [Population based norms of the Spanish version of the SF-12V2 for Murcia (Spain)]. Gac Sanit. 2011 Jan-Feb;25(1):50-61. doi: 10.1016/j.gaceta.2010.09.001. Epub 2010 Oct 25. Spanish. PubMed 20980078 ↗
  • Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998 Nov;51(11):1171-8. doi: 10.1016/s0895-4356(98)00109-7. PubMed 9817135 ↗
  • Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002 Feb;52(2):69-77. doi: 10.1016/s0022-3999(01)00296-3. PubMed 11832252 ↗
  • Morris JL, Rohay J, Chasens ER. Sex Differences in the Psychometric Properties of the Pittsburgh Sleep Quality Index. J Womens Health (Larchmt). 2018 Mar;27(3):278-282. doi: 10.1089/jwh.2017.6447. Epub 2017 Nov 20. PubMed 29154713 ↗
  • Beck SL, Schwartz AL, Towsley G, Dudley W, Barsevick A. Psychometric evaluation of the Pittsburgh Sleep Quality Index in cancer patients. J Pain Symptom Manage. 2004 Feb;27(2):140-8. doi: 10.1016/j.jpainsymman.2003.12.002. PubMed 15157038 ↗
  • Bisset LM, Evans K, Tuttle N. Reliability of 2 protocols for assessing pressure pain threshold in healthy young adults. J Manipulative Physiol Ther. 2015 May;38(4):282-7. doi: 10.1016/j.jmpt.2015.03.001. Epub 2015 Apr 27. PubMed 25925018 ↗
  • Fischer AA. Pressure algometry over normal muscles. Standard values, validity and reproducibility of pressure threshold. Pain. 1987 Jul;30(1):115-126. doi: 10.1016/0304-3959(87)90089-3. PubMed 3614975 ↗
  • Nie H, Arendt-Nielsen L, Andersen H, Graven-Nielsen T. Temporal summation of pain evoked by mechanical stimulation in deep and superficial tissue. J Pain. 2005 Jun;6(6):348-55. doi: 10.1016/j.jpain.2005.01.352. PubMed 15943956 ↗
  • Bajaj P, Bajaj P, Madsen H, Arendt-Nielsen L. A comparison of modality-specific somatosensory changes during menstruation in dysmenorrheic and nondysmenorrheic women. Clin J Pain. 2002 May-Jun;18(3):180-90. doi: 10.1097/00002508-200205000-00007. PubMed 12048420 ↗
  • Chesterton LS, Sim J, Wright CC, Foster NE. Interrater reliability of algometry in measuring pressure pain thresholds in healthy humans, using multiple raters. Clin J Pain. 2007 Nov-Dec;23(9):760-6. doi: 10.1097/AJP.0b013e318154b6ae. PubMed 18075402 ↗
  • Cleland JA, Childs JD, Whitman JM. Psychometric properties of the Neck Disability Index and Numeric Pain Rating Scale in patients with mechanical neck pain. Arch Phys Med Rehabil. 2008 Jan;89(1):69-74. doi: 10.1016/j.apmr.2007.08.126. PubMed 18164333 ↗
  • Reed BG, Carr BR. The Normal Menstrual Cycle and the Control of Ovulation. 2018 Aug 5. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from http://www.ncbi.nlm.nih.gov/books/NBK279054/ PubMed 25905282 ↗
  • Hampson E. A brief guide to the menstrual cycle and oral contraceptive use for researchers in behavioral endocrinology. Horm Behav. 2020 Mar;119:104655. doi: 10.1016/j.yhbeh.2019.104655. Epub 2019 Dec 23. PubMed 31843564 ↗
  • Mihm M, Gangooly S, Muttukrishna S. The normal menstrual cycle in women. Anim Reprod Sci. 2011 Apr;124(3-4):229-36. doi: 10.1016/j.anireprosci.2010.08.030. Epub 2010 Sep 3. PubMed 20869180 ↗
  • Rodrigues JC, Avila MA, Driusso P. Transcutaneous electrical nerve stimulation for women with primary dysmenorrhea: Study protocol for a randomized controlled clinical trial with economic evaluation. PLoS One. 2021 May 20;16(5):e0250111. doi: 10.1371/journal.pone.0250111. eCollection 2021. PubMed 34014922 ↗
  • Machado AFP, Perracini MR, Rampazo EP, Driusso P, Liebano RE. Effects of thermotherapy and transcutaneous electrical nerve stimulation on patients with primary dysmenorrhea: A randomized, placebo-controlled, double-blind clinical trial. Complement Ther Med. 2019 Dec;47:102188. doi: 10.1016/j.ctim.2019.08.022. Epub 2019 Aug 28. PubMed 31779988 ↗
  • Yokozuka M, Nagai M, Katsura R, Kenmyo K. Analgesia by Sacral Surface Electrical Stimulation for Primary Dysmenorrhoea. J Rehabil Med Clin Commun. 2020 Feb 27;3:1000027. doi: 10.2340/20030711-1000027. eCollection 2020. PubMed 33884129 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Apr 2026, 25 months.

Of 179 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 25 months is above that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 3 and three quarters within 17.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jun 2024 → Apr 2026 and completion Jun 2024 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2024
First posted
Jan 31, 2024
StartActual
Feb 22, 2024
Primary completionActual
Apr 13, 2026was Jun 2024
CompletionActual
Sep 23, 2026was Jun 2024
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 28, 2026
Primary completion
Jun 2024→Apr 13, 2026 (actual)
Sep 28, 2026
Study completion
Jun 2024→Sep 23, 2026 (actual)
Sep 28, 2026
Enrollment
30 (estimated)→60 (actual)
Sep 28, 2026
Eligibility
Maximum age none→50 Years
Sep 28, 2026
Interventions
Added Device: Transcutaneous Electrical Nerve Stimulation (TENS) during bleeding phase·Device: Transcutaneous Electrical Nerve Stimulation (TENS) during luteal phase·Device: Sham Transcutaneous Electrical Nerve Stimulation (TENS) during bleeding phase; removed Device: Transcutaneous Electrical Nerve Stimulation (TENS)
Sep 28, 2026
Primary outcomes
2 time frame changed, 3 removed, 1 description edited
What changed in the outcomes
  • RemovedPain: McGill Pain Index (MPQ)Time frame: Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days.
  • RemovedQuality of life related to menstruation: Specific quality of life questionnaire related to menstruation (CVM-22)Time frame: Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days.
  • RemovedQuality of life: SF12 Health QuestionnaireTime frame: Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days.
  • Time framePain: Numerical Pain Scale (NPRS)Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days. → Pain intensity on the first day of menstrual bleeding will be assessed, in addition to the three days preceding and following it, across three consecutive cycles.
  • Time framePressure pain threshold (PDU): Analog pressure algometer (Wagner FPX, United States)Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days. → Assessments will be conducted on the first day of menstrual bleeding (within 24h) across three consecutive cycles. In the second cycle, both groups will undergo two assessments instead of one, carried out before and after the first treatment session.
  • DescriptionPressure pain threshold (PDU): Analog pressure algometer (Wagner FPX, United States): how it is measured was reworded
Sep 28, 2026
Secondary outcomes
3 time frame changed, 3 added, 1 description edited
What changed in the outcomes
  • AddedQuality of life: SF12 Health QuestionnaireTime frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
  • AddedPain: McGill Pain Index (MPQ)Time frame: Pain assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
  • AddedQuality of life related to menstruation: Specific quality of life questionnaire related to menstruation (CVM-22)Time frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
  • Time frameAnxiety and Depresion: Hospital Anxiety and Depression Scale (HADS)Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days. → Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
  • Time frameCatastrophic thinking: Pain Catastrophizing Scale (PCS):Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days. → Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
  • Time frameSleep quality: Pittsburgh Sleep Quality Index (PSQI):Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days. → Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
  • DescriptionAnxiety and Depresion: Hospital Anxiety and Depression Scale (HADS): how it is measured was reworded
Sep 28, 2026
Title
The Effectivenes of Non-invasive Neuromodulation in Adult Women With Primary Dysmenorrhea, Through the TENS Stimulation at Different Times of MentrualMenstrual Cycle in Each Group
Sep 28, 2026
Design
Phase 3→Not applicable
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Recruiting→Completed
    Primary completion Jun 2024→Apr 13, 2026 (now actual)
    Study completion Jun 2024→Sep 23, 2026 (now actual)
    Enrollment 30 (estimated)→60 (actual)
    Eligibility Maximum age none→50 Years
    Primary outcomes 2 time frame changed, 3 removed, 1 description edited
    What changed in the outcomes
    • RemovedPain: McGill Pain Index (MPQ)Time frame: Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days.
    • RemovedQuality of life related to menstruation: Specific quality of life questionnaire related to menstruation (CVM-22)Time frame: Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days.
    • RemovedQuality of life: SF12 Health QuestionnaireTime frame: Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days.
    • Time framePain: Numerical Pain Scale (NPRS)Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days. → Pain intensity on the first day of menstrual bleeding will be assessed, in addition to the three days preceding and following it, across three consecutive cycles.
    • Time framePressure pain threshold (PDU): Analog pressure algometer (Wagner FPX, United States)Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days. → Assessments will be conducted on the first day of menstrual bleeding (within 24h) across three consecutive cycles. In the second cycle, both groups will undergo two assessments instead of one, carried out before and after the first treatment session.
    • DescriptionPressure pain threshold (PDU): Analog pressure algometer (Wagner FPX, United States): how it is measured was reworded
    Secondary outcomes 3 time frame changed, 3 added, 1 description edited
    What changed in the outcomes
    • AddedQuality of life: SF12 Health QuestionnaireTime frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
    • AddedPain: McGill Pain Index (MPQ)Time frame: Pain assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
    • AddedQuality of life related to menstruation: Specific quality of life questionnaire related to menstruation (CVM-22)Time frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
    • Time frameAnxiety and Depresion: Hospital Anxiety and Depression Scale (HADS)Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days. → Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
    • Time frameCatastrophic thinking: Pain Catastrophizing Scale (PCS):Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days. → Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
    • Time frameSleep quality: Pittsburgh Sleep Quality Index (PSQI):Baseline, immediately after treatment and at 28 days in bleeding phase and sham TENS, while in luteal phase will be done at baseline, at 7 days and at 28 days. → Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
    • DescriptionAnxiety and Depresion: Hospital Anxiety and Depression Scale (HADS): how it is measured was reworded
    Interventions Added Device: Transcutaneous Electrical Nerve Stimulation (TENS) during bleeding phase·Device: Transcutaneous Electrical Nerve Stimulation (TENS) during luteal phase·Device: Sham Transcutaneous Electrical Nerve Stimulation (TENS) during bleeding phase; removed Device: Transcutaneous Electrical Nerve Stimulation (TENS)
    Design Phase 3→Not applicable
    Title The Effectivenes of Non-invasive Neuromodulation in Adult Women With Primary Dysmenorrhea, Through the TENS Stimulation at Different Times of MentrualMenstrual Cycle in Each Group
    + 6 other changes: verification date, description, site details, contact details, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06233786
Lead sponsor
Naiara Benítez Aramburu
Responsible party
Naiara Benítez Aramburu (Principal investigator, Escoles Universitaries Gimbernat) — Sponsor-investigator
First posted
Jan 31, 2024
Start date
Feb 22, 2024
Primary completion
Apr 13, 2026
Completion
Sep 23, 2026
Last update
Sep 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion